Designed to efficiently manage large volumes of genetic data, GeneInsight will enable CellNetix’s diagnostics team to more quickly identify targeted treatments for a patient’s specific tumor type. The scalable system infrastructure and web-based deployment will also allow Cellnetix to build its own genetic knowedgebase for standardized interpretations across its network of laboratories.
“CellNetix has designed a custom assay Symgene, a 68-gene panel to effectively target tumor therapies. Our upcoming, expanded 200-gene panel will provide an even greater level of granularity; and we needed a solution that could scale to support the increased data set,” said Anna Berry, M.D., medical director of molecular diagnostics at CellNetix and scientific director, personalized medicine program, Swedish Cancer Institute.
“Pathology labs of all sizes are starting cancer genetic testing programs across the country. This collaboration with CellNetix will, in turn, help many such labs scale and grow their own, in-house NGS testing programs,” said Matthew Hawkins, president of Sunquest Information Systems.
CellNetix also sought a solution that could integrate with their various information systems. As a user of Sunquest’s anatomic pathology (AP) information system since 2007, CellNetix will now have integrated AP and genetic data for more efficient and complete clinical reports. Furthermore, GeneInsight will integrate genetic cancer content from CellNetix’s third-party curated content providers.
“Ultimately, we chose GeneInsight because of the strength of the product and its promise to meet some of our current challenges,” said Pat Cooke, chief information officer at CellNetix. “We also chose GeneInsight because of our relationship with Sunquest. We are impressed by the Sunquest leadership team and direction of the company. We believe that Sunquest will be able to deliver innovative solutions to accommodate our future needs as we continue to evolve our diagnostic services.”
GeneInsight is a genetics information system developed at the Partners HealthCare Laboratory for Molecular Medicine. In clinical use since 2005, its ongoing development is supported through a strategic alliance between Partners HealthCare and Sunquest.